UniQure (NASDAQ:QURE) Faces Setback with FDA Decision

Luca Issi from RBC Capital set a price target of $11 for UniQure (NASDAQ:QURE), indicating a potential upside of approximately 7.32%.The FDA's decision on insufficient trial data for marketing application has significantly impacted UniQure's stock price.Despite recent challenges, UniQure's market capitalization of approximately $646.84 million and a trading volume of 16,764,186 shares reflect ongoing investor interest.UniQure (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies for ...